ADAP Adaptimmune Therapeutics PLC

Price (delayed)

$4.03

Market cap

$627.91M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.96

Enterprise value

$613.61M

Highlights
The company's quick ratio has surged by 53% YoY and by 8% QoQ
The debt has declined by 7% year-on-year and by 4.1% since the previous quarter
The company's revenue has surged by 93% YoY but it fell by 8% QoQ
Adaptimmune Therapeutics's gross profit has surged by 93% YoY but it has decreased by 8% QoQ
Adaptimmune Therapeutics's net income has decreased by 7% QoQ

Key stats

What are the main financial stats of ADAP
Market
Shares outstanding
155.81M
Market cap
$627.91M
Enterprise value
$613.61M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.03
Price to sales (P/S)
172.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
168.99
Earnings
Revenue
$3.63M
EBIT
-$139.3M
EBITDA
-$132.16M
Free cash flow
-$120.29M
Per share
EPS
-$0.96
Free cash flow per share
-$0.77
Book value per share
$1.99
Revenue per share
$0.02
TBVPS
$2.64
Balance sheet
Total assets
$411.58M
Total liabilities
$102.42M
Debt
$22.74M
Equity
$309.16M
Working capital
$327.99M
Liquidity
Debt to equity
0.07
Current ratio
11.48
Quick ratio
10.3
Net debt/EBITDA
0.11
Margins
EBITDA margin
-3,639.7%
Gross margin
100%
Net margin
-3,847.1%
Operating margin
-3,897.8%
Efficiency
Return on assets
-30.1%
Return on equity
-39%
Return on invested capital
-37.4%
Return on capital employed
-36.6%
Return on sales
-3,836.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ADAP stock price

How has the Adaptimmune Therapeutics stock price performed over time
Intraday
-2.66%
1 week
-12.77%
1 month
-16.39%
1 year
-61.66%
YTD
-25.23%
QTD
-24.11%

Financial performance

How have Adaptimmune Therapeutics's revenue and profit performed over time
Revenue
$3.63M
Gross profit
$3.63M
Operating income
-$141.53M
Net income
-$139.69M
Gross margin
100%
Net margin
-3,847.1%
The company's revenue has surged by 93% YoY but it fell by 8% QoQ
Adaptimmune Therapeutics's gross profit has surged by 93% YoY but it has decreased by 8% QoQ
The net margin has grown by 47% year-on-year but it has declined by 17% since the previous quarter
ADAP's operating margin is up by 46% YoY but it is down by 16% QoQ

Growth

What is Adaptimmune Therapeutics's growth rate over time

Valuation

What is Adaptimmune Therapeutics stock price valuation
P/E
N/A
P/B
2.03
P/S
172.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
168.99
Adaptimmune Therapeutics's EPS has increased by 27% YoY but it has decreased by 7% from the previous quarter
Adaptimmune Therapeutics's equity has soared by 66% YoY but it has decreased by 9% from the previous quarter
ADAP's price to book (P/B) is 30% lower than its last 4 quarters average of 2.9 and 28% lower than its 5-year quarterly average of 2.8
The company's revenue has surged by 93% YoY but it fell by 8% QoQ
The P/S is 64% above the 5-year quarterly average of 105.3 but 52% below the last 4 quarters average of 356.9

Efficiency

How efficient is Adaptimmune Therapeutics business performance
The company's return on invested capital has surged by 56% YoY and by 6% QoQ
The return on equity has surged by 54% year-on-year
Adaptimmune Therapeutics's return on assets has surged by 50% YoY
Adaptimmune Therapeutics's ROS has increased by 48% YoY but it has decreased by 17% from the previous quarter

Dividends

What is ADAP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ADAP.

Financial health

How did Adaptimmune Therapeutics financials performed over time
The company's quick ratio has surged by 53% YoY and by 8% QoQ
ADAP's current ratio has soared by 50% YoY and by 13% QoQ
The debt is 93% smaller than the equity
Adaptimmune Therapeutics's equity has soared by 66% YoY but it has decreased by 9% from the previous quarter
ADAP's debt to equity is down by 46% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.